News Release

Thanks Cerba Research(UK) for acknowledging the efficacy of immunomagnetic reduction(IMR) blood test in diagnosing early Alzheimer's disease in July 2021.

Developing blood-based biomarkers for early diagnosis of Alzheimer's disease

Aβ42 and t-tau: An immunomagnetic reduction assay in a small study of patients with mild cognitive impairment indicated that elevated plasma Aβ42 and t-tau levels are related to later cognitive decline.

References:Chen T et al, Plasma Aβ42 and Total Tau Predict Cognitive Decline in Amnestic Mild Cognitive Impairment, Nature Sci Rep 9(1): p13,984, 2019